Sarepta therapeutics, inc. (SRPT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Products, net

100,448

100,113

99,041

94,668

87,011

84,415

78,486

73,529

64,604

57,277

45,954

35,011

16,342

5,421

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration

13,226

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from research contracts and other grants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,253

-

-

-

27

1,059

2,583

6,088

2,626

4,168

2,951

4,474

7,336

7,574

11,207

11,212

13,585

7,524

11,585

14,296

8,702

3,997

Total revenues

113,674

100,113

99,041

94,668

87,011

84,415

78,486

73,529

64,604

57,277

45,954

35,011

16,342

5,421

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)

12,622

15,567

13,037

15,919

12,063

13,135

8,741

6,735

5,582

3,546

3,078

506

223

130

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

136,144

223,141

133,949

113,266

90,553

146,207

86,584

122,848

46,204

44,441

34,239

58,908

29,119

70,749

34,349

44,348

38,826

41,376

36,673

29,180

39,165

30,832

21,852

20,641

20,906

25,076

21,087

12,984

13,762

12,834

10,914

13,849

14,805

18,701

15,610

17,750

14,801

9,059

6,931

Operating expenses:
Selling, general and administrative

82,768

81,424

75,429

67,393

60,566

64,220

53,044

47,156

43,341

32,221

28,176

36,069

26,216

22,937

22,184

17,752

20,876

24,329

15,090

12,927

22,697

13,917

12,882

12,213

10,303

10,399

8,014

7,054

6,127

4,869

3,565

2,915

3,281

3,884

3,185

3,960

5,026

3,440

4,733

Acquired in-process research and development

-

-

-

173,240

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

EXONDYS 51 litigation and license charges

-

-

-

-

-

-

-

-

-

-

25,588

2,839

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement and license charges

-

10,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of in-licensed rights

166

200

216

217

216

216

216

217

216

216

780

28

29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost and expenses

231,700

330,332

222,631

370,035

163,398

223,778

148,585

176,956

95,343

80,424

91,861

98,350

55,587

93,816

56,533

62,100

59,702

65,705

51,763

42,107

61,862

44,749

34,734

32,854

31,209

35,475

29,101

20,038

19,889

-

-

-

-

-

-

-

-

-

-

Operating loss

-118,026

-230,219

-123,590

-275,367

-76,387

-139,363

-70,099

-103,427

-30,739

-23,147

-45,907

-63,339

-39,245

-88,395

-56,533

-62,100

-59,702

-64,452

-51,763

-42,107

-61,862

-44,722

-33,675

-30,271

-25,121

-32,849

-24,933

-17,087

-15,415

-10,367

-6,905

-5,557

-6,874

-9,000

-11,271

-10,125

-5,531

-3,797

-7,667

Other income (loss):
Loss on change in warrant valuation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-4,256

3,784

3,251

-23,984

17,160

1,945

26,906

73,636

42,716

-13,488

-10,926

7,443

7,052

11,253

7,274

-3,578

-9,040

Gain from sale of Priority Review Voucher

108,069

-

-

-

-

-

-

-

-

0

0

0

125,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

7,420

4,773

2,510

862

172

-2,311

6,968

5,218

-4,485

1,287

184

184

335

-57

-209

-201

-68

-229

-176

256

303

306

193

181

99

45

63

-19

237

84

67

107

96

147

199

151

90

82

51

Total other income (loss)

100,649

-4,773

-2,510

-862

-172

-2,311

-6,968

-5,218

-4,485

-2,693

184

184

125,335

-57

-209

-201

-68

-229

-176

256

303

306

4,449

-3,603

-3,152

24,029

-17,097

-1,964

-26,669

-51,700

-42,649

13,595

-10,830

7,590

7,251

11,404

7,364

-3,496

-8,989

Loss before income tax expense

-17,377

-234,992

-126,100

-276,229

-76,559

-141,674

-77,067

-108,645

-35,224

-25,840

-45,723

-63,155

86,090

-

-

-62,301

-59,770

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

115

711

226

174

84

-779

-674

622

139

-1,842

2,011

-109

2,000

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-17,492

-235,703

-126,326

-276,403

-76,643

-140,895

-76,393

-109,267

-35,363

-23,998

-47,734

-63,046

84,090

-88,452

-56,742

-62,301

-59,770

-64,681

-51,939

-41,851

-61,559

-44,416

-29,226

-33,874

-28,273

-8,820

-42,030

-19,051

-42,084

-62,067

-49,554

8,038

-17,704

-1,410

-4,020

1,279

1,833

-7,293

-16,656

Write-down of short-term securities - available-for-sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

Realized gain on sale of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

Unrealized gains on investments, net of tax

574

-25

-7

63

118

-107

369

282

-264

-367

26

17

65

-120

-1

6

106

-110

18

-2

78

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

Total other comprehensive income

574

-25

-7

63

118

-107

369

282

-264

-367

26

17

65

-120

-1

6

106

-110

18

-2

78

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

Comprehensive loss

-16,918

-235,728

-126,333

-276,340

-76,525

-141,002

-76,024

-108,985

-35,627

-24,365

-47,708

-63,029

84,155

-88,572

-56,743

-62,295

-59,664

-64,791

-51,921

-41,853

-61,481

-

-

-

-

-

-

-

-

-62,067

-49,554

8,038

-17,704

-1,410

-4,020

1,279

1,833

-

-

Net (loss) income per share
Basic (loss) earnings per share

-

-

-

-

-

-

-

-

-

-

-

-1.15

1.53

-

-

-1.35

-1.31

-

-

-

-

-

-

-

-

-

-

-

-

-

-2.17

0.36

-

-

-0.18

0.06

0.02

-

-0.15

Diluted (loss) earnings per share

-

-

-

-

-

-

-

-

-

-

-

-1.15

1.50

-

-

-1.35

-1.31

-

-

-

-

-

-

-

-

-

-

-

-

-

-2.17

0.35

-

-

-0.18

0.06

0.02

-

-0.15

Weighted average number of shares of common stock used in computing:
Basic (loss) earnings per share

-

-

-

-

-

-

-

-

-

-

-

54,976

54,850

-

-

46,157

45,697

-

-

-

-

-

-

-

-

-

-

-

-

-

22,824

22,624

-

-

22,623

22,348

112,482

-

110,383

Diluted (loss) earnings per share

-

-

-

-

-

-

-

-

-

-

-

54,976

56,012

-

-

46,157

45,697

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22,623

23,153

121,285

-

110,383

Net loss per share - basic and diluted

-0.23

-3.16

-1.70

-3.74

-1.07

-2.05

-1.15

-1.67

-0.55

-

-0.78

-

-

-1.62

-1.18

-

-

-1.44

-1.25

-1.01

-1.49

-1.08

-0.71

-0.85

-0.75

-0.23

-1.24

-0.60

-1.32

-

-

-

-0.78

-

-

-

-

-0.07

-

Weighted average number of shares of common stock used in computing basic and diluted net loss per share

76,432

74

74,177

73,958

71,731

68,653

66,209

65,484

64,631

-

61,528

-

-

54,619

48,254

-

-

44,882

41,565

41,357

41,324

41,304

41,066

39,862

37,821

37,596

33,943

31,984

31,813

26,302

22,824

22,658

22,624

-

-

-

-

111,767

-